# Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

> **NCT06416436** · PHASE1 · WITHDRAWN · sponsor: **University of Kansas Medical Center**

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Atezolizumab
- **RADIATION:** Stereotactic Ablative Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT06416436
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-07-15
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-07-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Impasse during contract negotitations
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06416436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06416436, "Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06416436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*